Home
Clinical Resources Search
PQI: Selinexor (Xpovio®) Patient Management

Selinexor (Xpovio®) Patient Management

Download PQI pdf 0.19MB

Last Updated: November 14, 2023

By: Jeremiah Moore, PharmD

About this PQI

This PQI will provide background on the novel medication selinexor for patients with multiple myeloma (MM) who have received at least one prior therapy, relapsed, refractory multiple myeloma (RR-MM), and relapsed, refractory diffuse large b-cell lymphoma (RR-DLBCL) and discuss effective practices to maximize the use of selinexor therapy.

More About This PQI

PQI in Action Articles:

Selinexor_xpovio_patient_management pdf 1.21MB

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Diffuse Large B-Cell Lymphoma (DLBCL) Hematological Malignancies Multiple Meloma (MM) Multiple Myeloma Selinexor Xpovio

PQI

PQI: Ibrutinib Dosing Optimization

Author: Nick Bouchard, PharmD | Danielle Maciorowski, PharmD

Frequently Searched

Supported by

Selinexor (Xpovio®) Patient Management

About this PQI

More About This PQI

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Ibrutinib Dosing Optimization

PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management

PQI: Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PQI: Vorasidenib (Voranigo®)

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease

PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings

The PQI Podcast S3 Ep 13: The Importance of the Multidisciplinary Team

Readiness Tracker

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Treatment Support Kit: Tivozanib

Treatment Support Kit: Regorafenib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

PQI: Tafasitamab-cxix (Monjuvi®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

PQI: Loncastuximab tesirine-lpyl (Zynlonta®) in Relapsed/Refractory Large B-Cell Lymphoma

PQI: Glofitamab-gxbm (COLUMVI®) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

PQI in Action: Selinexor (Xpovio®)Patient Management

PQI Podcast S7 Ep 8: Sickle Cell Disease Insights

PQI: Ixazomib (Ninlaro®) In the Treatment of Multiple Myeloma

PQI: Isatuximab-irfc (Sarclisa®) Regimens in 1q21 gain/amplification Relapsed/ Refractory Multiple Myeloma

PQI: Isatuximab-irfc (Sarclisa®) In Patients with Relapsed/Refractory Multiple Myeloma

PQI: Elranatamab (Elrexfio®) for the treatment of Relapsed/Refractory Multiple Myeloma

PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma

PQI in Action: ClonoSEQ® Next Generation Sequencing for Minimal Residual Disease Testing in Multiple Myeloma

PQI in Action: Selinexor (Xpovio®)Patient Management

PQI in Action: Selinexor (Xpovio®)Patient Management

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings